GNRH1 and osteoporosis: Previous literature indicates that patients receiving long-term LHRH agonist therapy must carefully consider the risks associated with prolonged treatment (e.g., osteoporosis, fractures, anabolic muscle mass loss, and a tendency toward weight gain), although liver injury is rarely reported.